341 related articles for article (PubMed ID: 24325804)
21. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
22. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo.
Coles B; Fielding CA; Rose-John S; Scheller J; Jones SA; O'Donnell VB
Am J Pathol; 2007 Jul; 171(1):315-25. PubMed ID: 17591976
[TBL] [Abstract][Full Text] [Related]
23. Hitting a complex target: an update on interleukin-6 trans-signalling.
Waetzig GH; Rose-John S
Expert Opin Ther Targets; 2012 Feb; 16(2):225-36. PubMed ID: 22324903
[TBL] [Abstract][Full Text] [Related]
24. The role of interleukin-6 signaling in nervous tissue.
Rothaug M; Becker-Pauly C; Rose-John S
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
26. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease.
Schreiber S; Aden K; Bernardes JP; Conrad C; Tran F; Höper H; Volk V; Mishra N; Blase JI; Nikolaus S; Bethge J; Kühbacher T; Röcken C; Chen M; Cottingham I; Petri N; Rasmussen BB; Lokau J; Lenk L; Garbers C; Feuerhake F; Rose-John S; Waetzig GH; Rosenstiel P
Gastroenterology; 2021 Jun; 160(7):2354-2366.e11. PubMed ID: 33667488
[TBL] [Abstract][Full Text] [Related]
28. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
29. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.
Baran P; Nitz R; Grötzinger J; Scheller J; Garbers C
J Biol Chem; 2013 May; 288(21):14756-68. PubMed ID: 23564454
[TBL] [Abstract][Full Text] [Related]
30. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
31. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
[TBL] [Abstract][Full Text] [Related]
33. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
34. IL-6 Trans-signaling Controls Liver Regeneration After Partial Hepatectomy.
Fazel Modares N; Polz R; Haghighi F; Lamertz L; Behnke K; Zhuang Y; Kordes C; Häussinger D; Sorg UR; Pfeffer K; Floss DM; Moll JM; Piekorz RP; Ahmadian MR; Lang PA; Scheller J
Hepatology; 2019 Dec; 70(6):2075-2091. PubMed ID: 31100194
[TBL] [Abstract][Full Text] [Related]
35. sIL-6R: more than an agonist?
Knüpfer H; Preiss R
Immunol Cell Biol; 2008 Jan; 86(1):87-91. PubMed ID: 17724457
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells.
Valle ML; Dworshak J; Sharma A; Ibrahim AS; Al-Shabrawey M; Sharma S
Exp Eye Res; 2019 Jan; 178():27-36. PubMed ID: 30240585
[TBL] [Abstract][Full Text] [Related]
37. Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.
Lacroix M; Rousseau F; Guilhot F; Malinge P; Magistrelli G; Herren S; Jones SA; Jones GW; Scheller J; Lissilaa R; Kosco-Vilbois M; Johnson Z; Buatois V; Ferlin W
J Biol Chem; 2015 Nov; 290(45):26943-26953. PubMed ID: 26363066
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 biology is coordinated by membrane bound and soluble receptors.
Rose-John S
Acta Biochim Pol; 2003; 50(3):603-11. PubMed ID: 14515143
[TBL] [Abstract][Full Text] [Related]
39. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]